

# Epigenetics Market, 2012 to 2023

<https://marketpublishers.com/r/EB000C5EEBFEN.html>

Date: January 2018

Pages: 204

Price: US\$ 4,400.00 (Single User License)

ID: EB000C5EEBFEN

## Abstracts

Epigenetics Market: Epigenetics is a study of heritable changes in gene expression which involves the change in phenotype without changing genotype, which in turn affects the reading of genes by cells. Epigenetic changes are natural and regular processes but also influenced by various factors like lifestyle, environment, age and state of disease. Epigenetic modifications can manifest a common manner of cells which differentiate terminally to end up as liver cells, skin cells, brain cells etc. Epigenetic change may have more damaging effects which can lead to diseases like cancer. Systems like histone modification, non-coding RNA-associated gene silencing and DNA methylation are considered for initiation of epigenetic change sustainably.

### Market Outline: Global Epigenetics Market

The surge in the prevalence of cancer, improving funds and aids for the R&D activities, rise in the partnerships between pharmaceutical and biotechnology companies and research institutes, increase in epigenetics application in non-oncology diseases will propel the epigenetics. Moreover, improved advancements in epigenetics technology, untapped potential of emerging markets like India and China are expected to offer many opportunities for the growth of epigenetics market. However, high instrument cost and the dearth of skilled personnel are expected to hamper the growth of the epigenetics market.

The Epigenetics Market is classified on the basis of enzymes, kits and assays, instruments, application, end user, and geography.

Based on enzymes, the Epigenetics Market is segmented into the following

DNA polymerase

Acetylases

DNA ligases  
Methyltransferase  
RNA ligases  
Reverse Transcriptase  
Others

Based on instruments, the epigenetics Market is segmented into the following

Next generation sequencers  
Mass spectrometers  
Sonicators  
qPCRs  
Others

Based on application, the epigenetics market is segmented into the following

Oncology  
Cardiovascular diseases  
Metabolic diseases  
Inflammatory diseases  
Infectious diseases

Based on kits and assays, the epigenetics Market is segmented into the following

Deep sequencing kit  
Bisulfate conversion kit  
Methyltransferase assays  
Chip- seq kits  
Immunoprecipitation kits  
Histone assay

Based on end-user, the epigenetics Market is segmented into the following

Pharmaceutical and biotechnological companies  
Contract research companies  
Academic and Research Institutes

Epigenetics has triggered R&D for new drugs for various cancers, chronic and autoimmune disorders. For example, U.S.FDA approved ramucirumab/Cyramza by Eli

Lilly for use in combination with folfiri to treat metastatic colorectal cancer and Novartis's Farydak and Celgene's Istodax received FDA approval in 2015. Introduction of advanced technologies and potential investments on R&D activities are expected to fuel the growth of epigenetics. Currently, companies are focussing on detection of DNA methylation patterns and histone modification. For example, Epigenomic's EPI ProColon 1.0, Quest Diagnostic's ColoVantage, Abbott's Real Time mS9 are few tests which detect SepT9 DNA methylation biomarker for colorectal carcinoma. Development of high specific antibodies for accurate and rapid detection of modifications of histone core proteins. For example, Abcam developed a multiplex assay kit for the detection of various core histone protein modifications.

Geographically Epigenetics Market is segmented as Latin America, Europe, Asia-Pacific, North America, The Middle East & Africa. North America is expected to account for the largest market share in the regional market of epigenetics due to rise in prevalence of cancer, high funding on R&D, increasing acquisitions and collaborations among large pharma companies, high adaptation and awareness of new technologies and healthcare infrastructure. Asia Pacific is a lucrative market owing to the presence of favourable regulatory framework, high incidence and prevalence of diabetes, cancer and cardiovascular diseases among the population of Asia Pacific countries. Mexico, Brazil, and South Africa are expected to show significant growth due to rising economy, a high prevalence of diseases and presence of high unmet needs.

Some of the players in epigenetics market Illumina, Inc. (U.S.), Abcam plc. (U.K), QIAGEN N.V. (Netherlands), New England Biolabs, Inc. (U.S.), Merck & Co. (U.S.), Sigma-Aldrich Corporation (U.S.), Genedata AG (Switzerland), Cayman chemical company (U.S), Active Motif (U.S.), Thermo Fisher Scientific, Inc., (U.S.), Diagenode, Inc. (Belgium), Zymo Research Corporation (U.S.). and Episona Inc. (U.S).

In October 2016 Episode an epigenetics data company launched SEED a novel male fertility test to evaluate epigenetic changes on DNA to detect a risk of infertility and poor embryo development.

In June 2011, Cayman chemical company has adopted Genedata screener of Genedata, the company of advanced software solutions for drug discovery and life science research as a data management platform for cayman's new epigenetic screening laboratory.

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL EPIGENETICS MARKET INTRODUCTION**

#### 2.1. Global Epigenetics Market – Taxonomy

#### 2.2. Global Epigenetics Market –Definitions

##### 2.2.1. Enzyme

##### 2.2.2. Instruments

##### 2.2.3. Application

##### 2.2.4. Kits

##### 2.2.5. End-User

### **3. GLOBAL EPIGENETICS MARKET DYNAMICS**

#### 3.1. Drivers

#### 3.2. Restraints

#### 3.3. Opportunities/Unmet Needs of the Market

#### 3.4. Trends

#### 3.5. Global Epigenetics Market Dynamics – Factors Impact Analysis

#### 3.6. Global Epigenetics Market – Regulations

##### 3.6.1. U.S.

##### 3.6.2. Europe

### **4. GLOBAL EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

#### 4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 4.3. Market Opportunity Analysis

### **5. GLOBAL EPIGENETICS MARKET , BY ENZYME, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 5.1. DNA polymerase

##### 5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

##### 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

##### 5.1.3. Market Opportunity Analysis

## 5.2. Acetylases

5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

## 5.3. DNA ligases

5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

## 5.4. Methyltransferase

5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

## 5.5. RNA ligases

5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

## 5.6. Reverse Transcriptase

5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.6.3. Market Opportunity Analysis

## 5.7. Others

5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.7.3. Market Opportunity Analysis

## **6. GLOBAL EPIGENETICS MARKET FORECAST, BY INSTRUMENT, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 6.1. Next generation sequencers

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

### 6.2. Mass spectrometers

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

### 6.3. Sonicators

6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

#### 6.3.3. Market Opportunity Analysis

### 6.4. qPCRs

#### 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

#### 6.4.3. Market Opportunity Analysis

### 6.5. Others

#### 6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

#### 6.5.3. Market Opportunity Analysis

## **7. GLOBAL EPIGENETICS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 7.1. Oncology

#### 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

#### 7.1.3. Market Opportunity Analysis

### 7.2. Cardiovascular diseases

#### 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

#### 7.2.3. Market Opportunity Analysis

### 7.3. Metabolic diseases

#### 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

#### 7.3.3. Market Opportunity Analysis

### 7.4. Inflammatory diseases

#### 7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

#### 7.4.3. Market Opportunity Analysis

### 7.5. Infectious diseases

#### 7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

#### 7.5.3. Market Opportunity Analysis

## **8. GLOBAL EPIGENETICS MARKET FORECAST, BY KITS & ASSAY, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 8.1. Deep sequencing kit

#### 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis
- 8.2. Bisulfate conversion kit
  - 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 8.2.3. Market Opportunity Analysis
- 8.3. Methyltransferase assays
  - 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 8.3.3. Market Opportunity Analysis
- 8.4. Chip- seq kits
  - 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 8.4.3. Market Opportunity Analysis
- 8.5. Immunoprecipitation kits
  - 8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 8.5.3. Market Opportunity Analysis
- 8.6. Histone assay
  - 8.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 8.6.3. Market Opportunity Analysis

## **9. GLOBAL EPIGENETICS MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 9.1. Pharmaceutical and biotechnological companies
  - 9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 9.1.3. Market Opportunity Analysis
- 9.2. Contract research companies
  - 9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 9.2.3. Market Opportunity Analysis
- 9.3. Academic and Research Institutes
  - 9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 9.3.3. Market Opportunity Analysis



## **10. GLOBAL EPIGENETICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### **10.1. North America**

10.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.1.3. Market Opportunity Analysis

### **10.2. Europe**

10.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.2.3. Market Opportunity Analysis

### **10.3. Asia-Pacific**

10.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.3.3. Market Opportunity Analysis

### **10.4. Latin America**

10.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.4.3. Market Opportunity Analysis

### **10.5. Middle East and Africa**

10.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.5.3. Market Opportunity Analysis

10.6. Global Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Region, 2017 – 2023

## **11. NORTH AMERICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

11.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. DNA polymerase

11.1.2. Acetylases

11.1.3. DNA ligases

11.1.4. Methyltransferase

11.1.5. RNA ligases

11.1.6. Reverse Transcriptase

11.1.7. Others

11.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD



Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Next generation sequencers

11.2.2. Mass spectrometers

11.2.3. Sonicators

11.2.4. qPCRs

11.2.5. Others

11.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Oncology

11.3.2. Cardiovascular diseases

11.3.3. Metabolic diseases

11.3.4. Inflammatory diseases

11.3.5. Infectious diseases

11.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.4.1. Deep sequencing kit

11.4.2. Bisulfate conversion kit

11.4.3. Methyltransferase assays

11.4.4. Chip- seq kits

11.4.5. Immunoprecipitation kits

11.4.6. Histone assay

11.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.5.1. Pharmaceutical and biotechnological companies

11.5.2. Contract research companies

11.5.3. Academic and Research Institutes

11.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.6.1. U.S.

11.6.2. Canada

11.7. North America Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023

11.8. North America Epigenetics Market Dynamics – Trends

## **12. EUROPE EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

12.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 12.1.1. DNA polymerase
- 12.1.2. Acetylases
- 12.1.3. DNA ligases
- 12.1.4. Methyltransferase
- 12.1.5. RNA ligases
- 12.1.6. Reverse Transcriptase
- 12.1.7. Others
- 12.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 12.2.1. Next generation sequencers
  - 12.2.2. Mass spectrometers
  - 12.2.3. Sonicators
  - 12.2.4. qPCRs
  - 12.2.5. Others
- 12.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 12.3.1. Oncology
  - 12.3.2. Cardiovascular diseases
  - 12.3.3. Metabolic diseases
  - 12.3.4. Inflammatory diseases
  - 12.3.5. Infectious diseases
- 12.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 12.4.1. Deep sequencing kit
  - 12.4.2. Bisulfate conversion kit
  - 12.4.3. Methyltransferase assays
  - 12.4.4. Chip- seq kits
  - 12.4.5. Immunoprecipitation kits
  - 12.4.6. Histone assay
- 12.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 12.5.1. Pharmaceutical and biotechnological companies
  - 12.5.2. Contract research companies
  - 12.5.3. Academic and Research Institutes
- 12.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 12.6.1. Germany
  - 12.6.2. UK
  - 12.6.3. France

12.6.4. Spain

12.6.5. Italy

12.6.6. Russia

12.6.7. Poland

12.6.8. Rest of Europe

12.7. Europe Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023

12.8. Europe Epigenetics Market Dynamics – Trends

### **13. ASIA-PACIFIC EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

13.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. DNA polymerase

13.1.2. Acetylases

13.1.3. DNA ligases

13.1.4. Methyltransferase

13.1.5. RNA ligases

13.1.6. Reverse Transcriptase

13.1.7. Others

13.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Next generation sequencers

13.2.2. Mass spectrometers

13.2.3. Sonicators

13.2.4. qPCRs

13.2.5. Others

13.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Oncology

13.3.2. Cardiovascular diseases

13.3.3. Metabolic diseases

13.3.4. Inflammatory diseases

13.3.5. Infectious diseases

13.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.4.1. Deep sequencing kit

13.4.2. Bisulfate conversion kit

- 13.4.3. Methyltransferase assays
- 13.4.4. Chip- seq kits
- 13.4.5. Immunoprecipitation kits
- 13.4.6. Histone assay
- 13.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 13.5.1. Pharmaceutical and biotechnological companies
  - 13.5.2. Contract research companies
  - 13.5.3. Academic and Research Institutes
- 13.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 13.6.1. Japan
  - 13.6.2. China
  - 13.6.3. India
  - 13.6.4. ASEAN
  - 13.6.5. Australia & New Zealand
  - 13.6.6. Rest of Asia-Pacific
- 13.7. Asia-Pacific Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
- 13.8. Europe Epigenetics Market Dynamics – Trends

## **14. LATIN AMERICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 14.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 14.1.1. DNA polymerase
  - 14.1.2. Acetylases
  - 14.1.3. DNA ligases
  - 14.1.4. Methyltransferase
  - 14.1.5. RNA ligases
  - 14.1.6. Reverse Transcriptase
  - 14.1.7. Others
- 14.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.2.1. Next generation sequencers
  - 14.2.2. Mass spectrometers
  - 14.2.3. Sonicators

14.2.4. qPCRs

14.2.5. Others

14.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.3.1. Oncology

14.3.2. Cardiovascular diseases

14.3.3. Metabolic diseases

14.3.4. Inflammatory diseases

14.3.5. Infectious diseases

14.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.4.1. Deep sequencing kit

14.4.2. Bisulfate conversion kit

14.4.3. Methyltransferase assays

14.4.4. Chip- seq kits

14.4.5. Immunoprecipitation kits

14.4.6. Histone assay

14.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.5.1. Pharmaceutical and biotechnological companies

14.5.2. Contract research companies

14.5.3. Academic and Research Institutes

14.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.6.1. Brazil

14.6.2. Mexico

14.6.3. Argentina

14.6.4. Venezuela

14.6.5. Rest of Latin America

14.7. Latin America Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023

14.8. Latin America Epigenetics Market Dynamics – Trends

## **15. MIDDLE EAST AND AFRICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

15.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

15.1.1. DNA polymerase

- 15.1.2. Acetylases
- 15.1.3. DNA ligases
- 15.1.4. Methyltransferase
- 15.1.5. RNA ligases
- 15.1.6. Reverse Transcriptase
- 15.1.7. Others
- 15.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 15.2.1. Next generation sequencers
  - 15.2.2. Mass spectrometers
  - 15.2.3. Sonicators
  - 15.2.4. qPCRs
  - 15.2.5. Others
- 15.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 15.3.1. Oncology
  - 15.3.2. Cardiovascular diseases
  - 15.3.3. Metabolic diseases
  - 15.3.4. Inflammatory diseases
  - 15.3.5. Infectious diseases
- 15.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 15.4.1. Deep sequencing kit
  - 15.4.2. Bisulfate conversion kit
  - 15.4.3. Methyltransferase assays
  - 15.4.4. Chip- seq kits
  - 15.4.5. Immunoprecipitation kits
  - 15.4.6. Histone assay
- 15.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 15.5.1. Pharmaceutical and biotechnological companies
  - 15.5.2. Contract research companies
  - 15.5.3. Academic and Research Institutes
- 15.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 15.6.1. Gulf Cooperation Council (GCC) Countries
  - 15.6.2. Israel
  - 15.6.3. South Africa
  - 15.6.4. Rest of MEA

15.7. MEA Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023

15.8. MEA Epigenetics Market Dynamics – Trends

## **16. COMPETITION LANDSCAPE**

16.1. Strategic Dashboard of Top Market Players

16.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

16.2.1. Illumina, Inc. (U.S.)

16.2.2. Abcam plc. (U.K)

16.2.3. QIAGEN N.V. (Netherland)

16.2.4. New England Biolabs, Inc. (U.S.)

16.2.5. Merck & Co. (U.S.)

16.2.6. Sigma-Aldrich Corporation (U.S.)

16.2.7. Genedata AG(Switzerland)

16.2.8. Cayman chemical company (U.S)

16.2.9. Active Motif (U.S.)

16.2.10. Thermo Fisher Scientific, Inc., (U.S.)

16.2.11. Diagenode, Inc. (Belgium)

16.2.12. Zymo Research Corporation (U.S.).

16.2.13. Episona Inc. (U.S).

## **17. RESEARCH METHODOLOGY**

## **18. KEY ASSUMPTIONS AND ACRONYMS**



## I would like to order

Product name: Epigenetics Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/EB000C5EEBFEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EB000C5EEBFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970